Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diphenhydramine + sodium bicarbonate is a combination of two agents used primarily in the context of diphenhydramine overdose or toxicity. Diphenhydramine is a first-generation antihistamine that acts as an inverse agonist at the histamine H1 receptor, with additional antimuscarinic and local anesthetic (sodium channel blocking) properties. In overdose, it can cause anticholinergic toxicity and cardiac arrhythmias due to its blockade of cardiac sodium channels. Sodium bicarbonate is an alkalinizing agent commonly used to treat metabolic acidosis and as an antidote for certain drug toxicities involving sodium channel blockade. In cases of diphenhydramine-induced cardiotoxicity (such as wide complex tachycardia), intravenous sodium bicarbonate is administered to reverse QRS widening by counteracting the effects on cardiac sodium channels[2][3][9]. This combination does not represent a marketed pharmaceutical product but rather a therapeutic pairing used in emergency medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphenhydramine + sodium bicarbonate.